Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)

A carboxypeptidase that removes C-terminal lysine or arginine from peptides and proteins. Carboxypeptidase B2 (CPB2) is released into the circulation as a proenzyme which is activated by the THROMBIN-THROMBOMODULIN complex. Activated CPB2 is involved in modulating a variety of processes by cleaving and inactivating various circulating proteins and peptides that are its substrates including FIBRIN; KININS; and ANAPHYLATOXINS.

Also Known As:

Networked: 311 relevant articles (6 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Morser, John: 9 articles (10/2019 - 12/2003)
2.	Hendriks, Dirk: 8 articles (12/2022 - 03/2009)
3.	Meijers, Joost C M: 8 articles (10/2018 - 01/2002)
4.	Declerck, Paul J: 7 articles (01/2021 - 04/2007)
5.	Morser, J: 7 articles (06/2018 - 01/2008)
6.	Taguchi, Osamu: 7 articles (10/2013 - 06/2003)
7.	Colucci, Mario: 6 articles (01/2021 - 07/2003)
8.	Lisman, Ton: 6 articles (03/2017 - 01/2002)
9.	Gabazza, Esteban C: 6 articles (10/2013 - 02/2002)
10.	Gabazza, E C: 6 articles (04/2013 - 10/2001)

Related Diseases

1.	Thrombosis (Thrombus) 01/01/2010 - "A suitable inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) has the potential to be a novel treatment for thrombosis. " 12/01/2009 - "This study evaluated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) levels, TAFI gene polymorphisms and Clot Lysis Time (CLT) in pregnant patients with APS in relation to pregnancy outcome and thrombosis. " 06/01/2009 - "The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study." 06/01/2009 - "Studies on the relation between thrombin activatable fibrinolysis inhibitor (TAFI) and arterial thrombosis have produced conflicting results. " 10/01/2005 - "Several studies have suggested that thrombin-activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results have been contradictory. "
2.	Fibrosis (Cirrhosis) 07/01/2001 - "In this study, the role of the recently discovered inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI) in cirrhosis was examined. " 01/01/2008 - "Thrombin-activatable fibrinolysis inhibitor (TAFI) has been reported to affect wound healing and fibrotic processes, but its role in renal tubulointerstitial fibrosis remains unknown. " 01/01/2008 - "Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis." 04/01/2006 - "Thrombin-activatable fibrinolysis inhibitor (TAFI) is a strong suppressor of fibrinolysis, but its role in lung fibrosis is unknown. " 07/01/2003 - "Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis."
3.	Ischemic Stroke 01/01/2016 - "Thrombin-activatable fibrinolysis inhibitor (TAFI) activation following thrombolysis may affect thrombolysis effectiveness in acute ischemic stroke (AIS). " 01/01/2010 - "Procarboxypeptidase U (proCPU, TAFI) concentration in plasma is potentially related to thrombotic tendency, and elevated proCPU levels have been reported in ischemic stroke patients. " 10/01/2005 - "High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke." 10/01/2003 - "Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels." 02/01/2009 - "Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients."
4.	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/01/2008 - "Fenofibrate decreases thrombin-activatable fibrinolysis inhibitor levels and improves endothelial function in metabolic syndrome and, thus, suggests a potential for protection against cardiovascular effects. " 06/01/2008 - "Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome." 06/01/2008 - "This study aimed to assess concomitantly the effects of fenofibrate therapy on thrombin-activatable fibrinolysis inhibitor concentrations and endothelial functions in patients with metabolic syndrome. " 09/01/2005 - "Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor." 09/01/2005 - "To determine whether plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with type 2 diabetes were associated with components of metabolic syndrome (MS), including high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI)-1, and LDL cholesterol. "
5.	Allergic Rhinitis 11/01/2021 - "Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis." 11/01/2021 - "The objective of this study was to determine the role of thrombin-activatable fibrinolysis inhibitor (TAFI) as a candidate biomarker for therapeutic efficacy of sublingual immunotherapy (SLIT) and to identify the role of TAFI in the pathogenesis of allergic rhinitis (AR). "

Related Drugs and Biologics

1.	Antigens
2.	Biomarkers (Surrogate Marker)
3.	recombinant FVIIa (rFVIIa)
4.	Fenofibrate (CiL)
5.	Plasminogen Activator Inhibitor 1
6.	Plasminogen Activators (Plasminogen Activator)
7.	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)
8.	Enzymes
9.	Thrombin
10.	Tissue Plasminogen Activator (Alteplase)

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Therapeutics
3.	Stents
4.	Thrombectomy
5.	Liver Transplantation